Blog
RSS FeedPosted by Michael Wonder on 18 Nov 2015
Amgen's cholesterol-buster Repatha turned down for NHS use
18 November 2015 - NICE has turned down Amgen’s Repatha - the world’s first approved PCSK9 inhibitor - as an option ...
Posted by Michael Wonder on 18 Nov 2015
NICE says 'no' to personalised bowel cancer drugs
18 November 2015 - NICE has published interim guidance barring patients with advanced bowel cancer from routine NHS access to Merck ...
Posted by Michael Wonder on 17 Nov 2015
NICE: Kadcyla price still too high
17 November 2015 - Although retained for use through the Cancer Drugs Fund, Roche’s breast cancer combination treatment, Kadcyla (trastuzumab emtansine), ...
Posted by Michael Wonder on 05 Nov 2015
NICE not in favour of drug for neuroblastoma
5 November 2015 - It looks like children and adolescents with neuroblastoma will not be able to access United Therapeutics’ Unituxin ...
Posted by Michael Wonder on 04 Nov 2015
NICE gives green light to dry eye disease treatment in final draft guidance
4 November 2015 - NICE has published final draft guidance recommending ciclosporin (Ikervis) manufactured by Santen Pharmaceutical) for treating severe keratitis ...
Posted by Michael Wonder on 28 Oct 2015
NICE publishes final drug recommendations for the treatment of 3 separate medical conditions
28 October 2015 - The National Institute for Health and Care Excellence has published its final recommendations for paclitaxel (nanoparticle ...
Posted by Michael Wonder on 22 Oct 2015
NICE draft guidance recommends treatments for arthritis in children
21 October 2015 - Health care guidance body NICE has today published final draft guidance recommending 4 drugs for treating a ...
Posted by Michael Wonder on 22 Oct 2015
NICE issues draft guidance on ezetimibe for primary hypercholesterolaemia
20 October 2015 - NICE has today published draft guidance recommending ezetimibe (Ezetrol, Merck Sharp & Dohme) as an option for ...
Posted by Michael Wonder on 22 Oct 2015
NICE approval of new hepatitis drug could result in £700m bill for NHS
21 October 2015 - The National Institute for Health and Care Excellence has approved another treatment for hepatitis C, presenting NHS ...
Posted by Michael Wonder on 16 Oct 2015
NICE draft guidance recommends vortioxetine (Brintellix) for treating major depressive episodes
16 October 2015 - In final draft guidance issued today NICE has recommended vortioxetine (Brintellix, Lundbeck) for some adults with major ...
Posted by Michael Wonder on 16 Oct 2015
NICE asks for further evidence for the benefits of a new treatment for Duchenne muscular dystrophy to justify its very high cost
16 October 2015 - In draft guidance produced by its Highly Specialised Technologies programme, NICE has asked for further clarification from ...
Posted by Michael Wonder on 13 Oct 2015
NICE launches initiative to speed up adoption of health technologies
13 October 2015 - NICE is introducing a new service, the Office for Market Access (OMA), an initiative to work with ...
Posted by Michael Wonder on 09 Oct 2015
Another NICE backing for Merck's Keytruda in skin cancer
9 October 2015 - The National Institute for Health and Care Excellence has given its blessing for the use of Merck’s ...
Posted by Michael Wonder on 07 Oct 2015
NICE gives green light to pembrolizumab for advanced skin cancer
8 October 2015 - NICE recommends that the drug pembrolizumab (also called Keytruda and manufactured by Merck, Sharp & Dohme) is ...
Posted by Michael Wonder on 07 Oct 2015
Fast-tracked skin cancer drug pembrolizumab gets approval
7 October 2015 - A new drug for advanced skin cancer should be made available on the NHS in England, experts ...